ABSTRACT
Objective To determine the association between smoking and progression of COVID-19.
Design A meta-analysis of 12 published papers.
Data Source PubMed database was searched on April 6, 2020.
Eligibility criteria and data analysis We included studies reporting smoking behavior of COVID-19 patients and progression of disease. Search terms included “smoking”, “smoker*”, “characteristics”, “risk factors”, “outcomes”, and “COVID-19”, “COVID”, “coronavirus”, “sar cov-2”, “sar cov 2”. There were no language limitations. One author extracted information for each study, screened the abstract or the full text, with questions resolved through discussion among both authors. A random effects meta-analysis was applied.
Main Outcome Measures The study outcome was progression of COVID-19 among people who already had the disease.
Results We identified 12 papers with a total of 9,025 COVID-19 patients, 878 (9.7%) with severe disease and 495 with a history of smoking (5.5%). The meta-analysis showed a significant association between smoking and progression of COVID-19 (OR 2.25, 95% CI 1.49-3.39, p=0.001). Limitations in the 12 papers suggest that the actual risk of smoking may be higher.
Conclusions Smoking is a risk factor for progression of COVID-19, with smokers having higher odds of COVID-19 progression than never smokers. Physicians and public health professionals should collect data on smoking as part of clinical management and add smoking cessation to the list of practices to blunt the COVID-19 pandemic.
What is already known on this topic
Smoking increases risk and severity of pulmonary infections because of damage to upper airways and a decrease in pulmonary immune function.
What this study adds
Smoking is associated with COVID-19 severity.
Smoking history should be part of clinical management of COVID-19 patients and cessation should be added to the list of practices to blunt the COVID-19 pandemic.
Introduction
COVID-19, the coronavirus-transmitted infectious disease, has caused a worldwide pandemic. Smoking1,2 and e-cigarette use3 increase risk and severity of pulmonary infections because of damage to upper airways and a decrease in pulmonary immune function. In particular, smokers have a higher risk of infection and mortality from Cov-MERS.4 Two reviews5,6 of the first 5 papers presenting data on smoking and COVID-19 reached different conclusions. Another review described 6 published case series presenting data on smoking among COVID-19 patients but did not draw a conclusion about the association of severity of COVID-19 with smoking.7 We reviewed and summarized 12 papers presenting data on the association between smoking and severity of COVID-19.
Methods
We conducted a systematic search using PubMed database on April 6, 2020, with the search term: ((smoking) OR (characteristics) OR (risk factors) OR (outcomes) OR (smoker*)) AND ((COVID-19) OR (COVID) OR (coronavirus) OR (sars cov-2) OR (sars cov 2)) for studies published between January 1, 2020 and April 6, 2020. There were no language restrictions. A total of 396 studies were retrieved through the search, of which 12, 10 from China,8-17 1 from Korea,18 and 1 from the US,19 included data on smoking behavior and COVID-19 disease progression (Table 1). Ten studies8,10-18 were based on hospitalized patients and two9,19 included both hospitalized patients and outpatients.
The exposure group is those who had a history of smoking (current smokers or former smokers) and unexposed group was never smokers. Five studies8,10,12,14,17assessed whether the patient was a “current smoker,” three studies9,16,19 assessed whether the patient was a current or former smoker (as separate categories), and four studies11,13,15,18 assessed whether the patent had a “history of smoking” (current or former).
Outcome is progression of COVID-19 to more severe or critical conditions or death (Table 1). Two studies14,16 categorized the outcome as severe (respiratory distress with respiratory rate ≥ 30/min, or oxygen saturation ≤93% at rest, or oxygenation index ≤300 mmHg, based on the diagnostic and treatment guideline for SARS-CoV-2 issued by Chinese National Health Committee16) or mild, three8,11,12 categorized the outcome as progression or improvement, two10,19 categorized the outcome as ICU admission or non-ICU admission, one9 categorized the outcome as the primary composite end point (ICU admission, the use of mechanical ventilation, or death) or not, two15,17 categorized the outcome as death or survivor, one13 categorized the outcome as the occurrence of severe cases (without defining severe) or death or mild, and one18 categorized the outcome as clinical deterioration during the hospitalization and needed supplemental oxygen therapy.
We computed unadjusted odds ratios (OR) and 95% confidence interval (CI) for each study using the number of smokers (current and former) and never smokers with and without disease progression. Random effects meta-analysis was performed using the Stata 14.0 metan command and using metabias command with Harbord and Peters to test for the presence of publication bias.
Patients or the public were not involved in the design, or conduct, or reporting of our research. We will widely disseminate our findings working with the media and interested clinical and public health groups.
Results
A total of 9,025 COVID-19 patients included in our meta-analysis, 878 of whom (9.7%) experienced disease progression and 495 with a history of smoking (5.5%). A total of 88 patients with a history of smoking (17.8%) experienced disease progression, compared with 9.3% of never smoking patients.
The meta-analysis showed an association between smoking and COVID-19 progression (OR 2.25, 95% CI 1.49-3.39, p=0.001) (Figure 1). There was not significant heterogeneity among the studies (I2=28.9%, p=0.162) or publication bias (Harbord’s p=0.155, Peters’ p=0.668).
Discussion
Our analysis confirms that smoking is a risk factor for progression of COVID-19, with smokers having 2.25-times the odds of severe COVID-19 outcomes than never smokers. This finding contrasts with an earlier meta-analysis,6 which included only 5 studies and used a non-standard method to compute the meta-analysis. The finding that smoking is associated with COVID-19 progression is not surprising because of the adverse effects of smoking on pulmonary immune function.1,2
Our study has several limitations.
The definition of “smoking” sometimes includes former smokers and sometimes does not. Only three studies9,16,19 separated current and former smokers in different categories, which was not enough data to do a meta-analysis for current and former smokers separately. Because the lung recovers after someone stops smoking, including former smokers in the exposed group biases the effect estimate to the null.
Reported smoking prevalence patients in all studies was substantially below smoking prevalence in the corresponding populations. Smoking prevalence in the 10 studies in China ranged from 3.8% to 14.6% vs 27.7% (52.1% for men and 2.7% for women) in the population in 2015,20 18.5% in the Korean patients vs. 21.1%21 (37.0% for men and 5.2% for women) in 2017, and 3.6% in the US patients vs. 13.7%22 (15.6% for men and 12.0% for women) in 2018. It is highly likely that many smokers were misclassified as nonsmokers, which also biases the risk estimate toward the null.
We computed and assessed unadjusted odds ratios based on the numbers of patients reported in the studies. Only one11 of the studies reported unadjusted and adjusted ORs using multivariate analysis; after adjusting for confounding, the effect of smoking on disease severity was higher (unadjusted: OR 12.19, 95% CI 1.76-84.31, p=0.011; adjusted: OR 14.29, 95% CI 1.58-25.0, p=0.018).
None of these studies assessed e-cigarette use.
All these limitations suggest that this analysis underestimates the risk of smoking in terms of increasing COVID-19 severity.
All 12 studies were of patients who had already developed COVID-19, so the risk estimate we report does not represent the effect of smoking on the risk of contracting COVID-19 in the general population. As population-level testing ramps up, it would be useful to collect data on smoking and e-cigarette use to determine what risks these behaviors impose in terms of infection.
Conclusions
Smoking is associated with COVID-19 disease progression. Physicians and public health professionals should collect data on smoking and, given the pulmonary effects of e-cigarettes,3 e-cigarette use, as part of routine clinical assessments and add smoking cessation to the list of practices to blunt the COVID-19 pandemic.
Data Availability
All data are included in the manuscript.
FUNDING
This work was supported by National Institute of Drug Abuse grant R01DA043950, cooperative agreement U54HL147127 from the National Heart, Lung, and Blood Institute and the Food and Drug Administration Center for Tobacco Products and the Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH or the Food and Drug Administration. The funding sources for this study had no role in the study design, data collection, data analysis, data interpretation, or the writing of the manuscript.
COMPETITING INTERESTS
All authors have completed the Unified Competing Interest form (available on request from the corresponding author) and declare that the work was supported as described in the funding statement above. The authors have no financial relationships with any organisations that might have an interest in the submitted work in the previous three years and no other relationships or activities that could appear to have influenced the submitted work.
CONTRIBUTORSHIP
RP developed the idea for the study, collected, analyzed the data, and wrote the first draft of the manuscript. SAG assisted with revising and refining the manuscript. Both authors affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.
ETHICAL APPROVAL
Not required.
DATA SHARING STATEMENT
All data used to prepare this paper are available from the cited sources.
